Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We tested whether nuclear imaging with indium111 (111In)-labeled murine monoclonal (MoAb) anticarcinoembryonic antigen (anti-CEA) ZCE-025 antibody could detect recurrent disease in patients with a rising serum CEA level but negative findings for computed tomographic (CT) scans of the abdomen and pelvis, chest radiograph, and colonoscopy or barium enema. Twenty patients with a history of completely resected CEA-producing adenocarcinoma (18 with colon cancer, one with breast cancer, and one with Hodgkin's disease) and a rising serum CEA level were given an intravenous infusion of 2 mg of 111In-labeled ZCE-025 mixed with 38 mg of unlabeled ZCE-025. Planar and single-photon emission CT (SPECT) scans were acquired at 72 and 144 hours, and in 19 of the 20 patients these were positive. Of those 19, 13 underwent exploratory surgery, and cancer was found in 10, and two had a diagnostic biopsy, which confirmed cancer. Three patients who had negative laparotomies and all four patients who did not undergo surgery or biopsy were followed radiologically. In all seven, cancer was subsequently detected at the sites suggested by the ZCE-025 scan. Thus, tumor was confirmed in all 19 patients with positive scans. Five of 13 patients who were explored benefited from the study and the exploratory laparotomy, as disease was entirely resected in four or was subjected to definitive radiation therapy to the pelvis in the fifth. In two additional patients who were not explored, MoAb imaging resulted in definitive therapy to regionally confined recurrent disease. 111In-labeled anti-CEA MoAb ZCE-025 scanning in patients with rising CEA successfully imaged metastatic colorectal cancer that eluded detection by other methods and affected the care given to some. These results suggest an important role for 111In-labeled ZCE-025 scanning among patients with rising CEA and otherwise occult metastatic cancer.
 ...
PMID:Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. 219 20

The article describes the case history of a 31 year old woman with a solitary intracranial metastasis from Hodgkin's lymphoma, and reviews the relevant literature. Metastasis to the central nervous system from Hodgkin's disease is uncommon. This affection is usually a result of metastasis to the meninges or bone, or of direct extension from paracranial or paraspinal lymph node involvement. Hematogenous metastasis of Hodgkin's disease confined to the brain is rare. Affection of the central nervous system is most common in lymphocyte depletion Hodgkin's disease. A higher frequency is seen in advanced clinical stages. The prognosis is poor.
 ...
PMID:[Cerebral metastasis in Hodgkin's disease]. 225 37

Due to the morbidity of open tissue biopsy, the cytologic diagnosis of pancreatic carcinoma by fine needle aspiration or examination of biliary tree fluid is highly desirable. Immunohistochemistry with monoclonal antibody B72.3 has been advocated as an adjunct in the identification of tumor cells in body fluids. To assess its usefulness as an adjunct in the diagnosis of pancreatic carcinoma, we examined cytologic specimens of the pancreas from 35 patients [24 pancreatic carcinoma, 6 metastases (4 adenocarcinoma and 1 each of Hodgkin's disease and melanoma), 5 with benign conditions] with an immunohistochemical procedure using B72.3 directly over the Papanicolaou-stained slides. Of the pancreatic carcinomas, 21 of 24 (87%) were cytologically positive and 21 of 24 (87%) marked with B72.3. With both techniques, 23 of 24 cases (96%) could be identified. Three of four metastatic adenocarcinomas were positive by both cytology and B72.3. No staining occurred in the metastatic melanoma, Hodgkin's disease, or 3 of 5 benign conditions. In two benign duodenal aspirates, an unusual reticular B72.3 staining occurred in the mucin of acinar and goblet cells which could be misinterpreted as positive staining. In our experience, B72.3 enhances the sensitivity of the cytologic diagnosis of pancreatic cancer. Unrecognized single tumor cells, cytologically uninterpretable cells, and tumor cell clusters that could be misinterpreted as reactive epithelium mark with B72.3. Care should be taken to avoid misinterpretation of nonspecific mucin staining with this antibody.
 ...
PMID:Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. 246 86

Neoadjuvant chemotherapy can be used before radiotherapy to combat microscopic metastatic loci and to facilitate irradiation. Improvement in the survival time by impeding the dissemination of metastases seems to be real for breast cancer, but has not been observed to date in randomized studies of ENT cancers. Neoadjuvant chemotherapy in Hodgkin's disease has improved survival time and tolerance to irradiation, allowing a lowering of the total doses used and the volumes irradiated. In breast and ENT cancers, it has become possible, due to tumor regression, to replace mutilating treatments with more conservative ones consisting of radiotherapy alone, without increasing the risk of local relapse. Indeed, it is in this domain that neoadjuvant chemotherapy is the most useful. Two important conditions must be met for its successful application: a) a sufficiently effective regimen must be chosen, in order to prevent tumor growth prior to irradiation (which would aggravate the prognosis); and b) an accurate identification and localization of the tumor before undertaking any treatment so as to not detract from the effectiveness of the radiotherapy.
 ...
PMID:[Radiotherapy with neoadjuvant chemotherapy]. 251 29

The authors presented in their first note generalities concerning the normal and pathological structure of bone marrow (BM), based on their personal experience (1,500 BMB) and on the literature. A short historical survey and the adopted research method are presented. The advantage of Burkhardt's myelotomy with its technical process by embedding in synthetic resins to avoid decalcification are discussed. The authors have used Jamshidi's cannula (or some other similar needle) with the subsequent embedding in paraffin after decalcification. Further papers will analyse the approach, by BMB, of the myeloproliferative disorders, myelodysplasia, lymphomas and Hodgkin's disease, cancer metastases and medullar aplasia.
 ...
PMID:Bone marrow biopsy (BMB). I. Generalities, material and method, normal structure of bone marrow, pathological conditions. 252 55

Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 10(9)/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 24% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.
 ...
PMID:High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. 256

A patient with bilateral renal metastases from non Hodgkin's malignant lymphoma originating in the aortocaval abdominal lymph nodes was treated with chemotherapy. Initially, methotrexate (20 mg/m2), vincristine (0.6 mg/m2), cyclophosphamide (500 mg/m2), adriamycin (20 mg/m2), and bleomycin (30 mg/m2) were given on day 1, cisplatinum (50 mg/m2) was given on day 2, and prednisolone (20 mg/body) was given from day 1 to 3 (MVP-CAB regimen). Since the patient was 74 years old and had slight renal dysfunction, for the first and second courses of this therapy, methotrexate and cisplatinum were administered at 60% of the usual dose and the other 4 anticancer agents at 70% of the usual dose. Only prednisolone was given at the full dose. From the third course the 6 anticancer agents were used at 70% of the normal dose. Administration was performed every 4 weeks until the third course, and every 8 weeks after the fourth course (total number of cycles of MVP-CAB: 8 cycles). A marked improvement of the general state and a reduction of the tumor size were noted following treatment. Since regrowth of the residual tumor occurred, as second line chemotherapy cytosine arabinoside (100 mg/m2) on day 1, ifosfamide (1 g/m2) on day 1 to 2, etoposide (100 mg/m2) plus prednisolone (20 mg/body) on day 1 to 3 were administered (AraC-VIP regimen). The timing of administration was similar to that of the MVP-CAB regimen. More than 50% tumor reduction was obtained with this regimen. The total survival time since the beginning of chemotherapy is 2 years to date.
 ...
PMID:[A case of bilateral renal metastases from non Hodgkin's malignant lymphoma]. 261 83

From September 1984 to March 1989, 57 children received intraoperative radiotherapy as part of a multidisciplinary tumor treatment. Their age ranged from 2 to 18 years. Tumor types: osteosarcoma, 21; Ewing's sarcoma, 19; soft tissue sarcomas, 6; neuroblastoma, 5; Wilm's tumor, 3; Hodgkin, 1; glioma, 1, and malignant pheochromocytoma, 1. In 44 patients the disease was localized while 13 had distant metastases. Intraoperative radiotherapy was used in 48 previously untreated patients as part of a radical treatment program and in 9 cases as an effort to rescue local failures (5 in previously irradiated areas). The intraoperative radiation field included the surgically exposed tumor or tumor bed, and the single doses ranged from 10 to 20 Gy, with 6-20 MeV electrons. With a median follow up time of 25 months (4 to 51 + months) 44 out of 57 patients are alive without local recurrence and 13 have died from tumor (6 with local progression). Intraoperative radiotherapy seems to be a feasible treatment which might promote local control in pediatric tumors.
 ...
PMID:[Intraoperative radiotherapy in the multidisciplinary treatment of malignant tumors in children. Preliminary results]. 263 10

The authors evaluated percutaneous aspiration biopsies of intrathoracic lesions in 348 patients where the obtained cytological results were compared with the histological finding from resections or post-mortem preparations. In 274 patients malignant and in 74 benign disease was confirmed. In the differentiation of malignant and benign disease the sensitivity of cytology was 84.3%, the specificity 91.9% and the accuracy 85.9%. The type of bronchogenic carcinoma was correctly diagnosed by cytological examination in 69.5%, in squamous cell carcinoma in 76.8%, in small-cell carcinoma in 80% and in adenocarcinoma in 59.1%. The same cytological finding as in the primary tumour was recorded in 73.5% of the patients with metastases in the lungs. Less favourable results as regards assessment of the type of tumour were obtained in other tumours, in particular in lymphogranulomas and non-Hodgkin lymphomas. In 25% it proved possible to assess by cytological examination the type of benign lung tumour.
 ...
PMID:[Percutaneous transthoracic aspiration biopsy: the reliability of cytological diagnosis of intrathoracic tumors]. 269 94

A radiologic evaluation in nine patients with cervical adenopathy because of metastatic disease at a known or unknown primary site, inflammatory lymphadenitis or with masses simulating with cervical adenopathy was done. All patients were examined normally by an oral and maxillofacial or E.N.T. surgeon before the radiologic evaluation with CT, ultrasonography and/or sialography. CT was done in seven out of nine patients as the unique technique or in combination with ultrasonography and/or sialography, while ultrasonography was used in two of the cases as a unique imaging technique and in one case in combination with a CT examination, without any intravenous contrast administration. A primary site was diagnosed in five cases, while in a sixth case was not diagnosed. In an eighth case of submandibular nodal enlargement, the diagnosis of Hodgkin's disease was established after a biopsy. For the last two cases the diagnosis of tuberculous cervical lymphadenopathy was confirmed. From the above cases it is clearly shown that computerized tomography, especially with intravenous contrast administration, ultrasonography and sialography in some of the cases, are necessary as routine examinations, before a diagnosis of cervical metastatic disease is to be done.
 ...
PMID:[Radiologic evaluation of cervical metastatic adenopathy]. 270 Dec 31


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>